Innovation without borders
Our research and development teams across Japan, Europe and the US design next generation diagnostic solutions, from neurological biomarkers that are transforming Alzheimer’s disease care to ultra-sensitive detection platforms that expand diagnostic accuracy across a wide range of conditions. With more than 12% of base revenue invested in R&D, we remain at the forefront of diagnostic assay innovation.
Across the world, we prove that our innovations work in real clinical practice through partnerships with leading laboratories, including extensive use of our fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform. This real-world validation gives our global CDMO partners confidence that our diagnostic solutions will perform reliably in their markets.
Related links:
Leading the neuro revolution
Nowhere is our impact more visible than in the field of neurological disease diagnostics. Our work builds on decades of innovation – starting with the CSF-based expertise gained through the acquisition of Innogenetics in 2010 and evolving to today’s blood-based breakthroughs such as the FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test. With the added strengths brought in through the acquisition of ADx NeuroSciences, we continue to develop novel biomarkers that enable simpler, less-invasive diagnosis of neurodegenerative diseases.
Our neurological biomarker pipeline extends far beyond Alzheimer’s disease including biomarkers for conditions such as multiple sclerosis (MS), Parkinson’s disease, and other motor neuron diseases such as amyotrophic lateral sclerosis (ALS) – creating the marker portfolio that will define brain health diagnostics and neurodegenerative disease testing for the next decade.
Related links:
Open partnership model
What makes us different is how we share innovation. While others guard their technology carefully, we have embraced an open business model that prioritizes patient access over corporate boundaries. Our CDMO partnerships with leading diagnostic companies worldwide enable breakthrough diagnostics to reach global markets faster than ever before.
From supplying diagnostic raw materials and reagents to providing complete biomarker development, manufacturing, and regulatory services, we offer everything partners need to bring innovative diagnostics to their customers. This collaboration creates exponential impact – allowing our innovations to multiply across our own and partner diagnostic platforms, reaching millions more patients than we could serve alone.
Related links:
Fujirebio Europe and the ISO 14001 standard
At Fujirebio Europe N.V. we have always given great value to the environment. This environmental awareness is embedded throughout our organization and has been valued by implementing an Environmental Management System (EMS). Since November 25, 2013 our company has been officially certified for our EMS which fulfils the requirements of the international standard ISO 14001:2015. The Scope, Policy, Objectives and Certificate are listed below.
Scope
Development, manufacturing and related administrative services of in vitro diagnostic and research kits and instruments.
Policy & Aim
It is Fujirebio Europe's environmental policy to develop and produce diagnostic products with environmental care and respect for a safe and healthy workplace. Our corporate values of Inspiration, Result Orientation, Teamwork and Care are woven in every facet of our commitment to manage environmental aspects as an integral part of our business. So Together we foster Inspiration and turn it into sustainable Solutions which express Care for the environment.
It is our aim to comply with applicable legal and other requirements and to reduce the impact of our operations by preventing and controlling pollution and by reducing the use of hazardous raw materials. Fujirebio Europe engages to continually improve in environmental performance.
Objectives
Fujirebio Europe has the intention to keep on maintaining an Environmental Management System compliant to ISO 14001:2015 and engages to reduce:
- Paper use (cfr. digitalization, e-invoicing for Belgian B2B transactions, …).
- Energy consumption and transition to sustainable energy sources as much as possible (cfr. replacement of IT material, Installation and usage of sonar panels, installation of extra charging points for electrical cars on site, retrofit TL lightning to led, …).
- CO2 emission during transport (cfr. promote sustainable mobility for employees, electrical company cars, increase local Lp production, study on concentrated reagents, …).
- The use of hazardous materials (cfr. IVD kits & instruments, R&D projects, waste collection optimalisation, …)
- Water use (replacement installations with lower water usage, study projects on optimalisations,…)
Certificate
Download a copy of our ISO 14001:2015 Certificate here:
